Michael K. Sergesketter
Analyst · Gabelli & Company. Your line is open. Please go ahead
Thanks Don. During my comments, I'll be referring to the slide deck Don mentioned, which can be found on our Investor Relations Web-site, within the Events and Presentations tab, or if you are listening via the Webcast, you can find it in the Downloads tab on the Webcast portal. As shown on Slide 3, our second quarter net sales were a record $258.2 million, which was a 12% increase compared to net sales of $230.3 million in the prior year second quarter. Partially assisting in the increase from a year ago was a favorable exchange rate movement which affected our net sales growth by 3%. Slide 4 represents our net sales mix by vertical market. Comparing our net sales by vertical to the same quarter a year ago, net sales in our automotive vertical were up over 20% compared to a year ago to a new quarterly record of $116.4 million. The increase from a year ago was largely due to the ramp-up of new program introductions and strong demand in North America and Europe. While our China automotive sales were down year-over-year, we did see a nice improvement sequentially from the prior quarter. Our medical vertical was up by double digits compared to Q2 last year, primarily from the ramp-up of new programs. Our industrial vertical was up from a year ago as a result of the continued ramp-up of new product launches related to smart metering devices as well as increased demand for our climate control products. Lastly, our public safety vertical was down by double-digits from the prior year second quarter as a result of lower overall demand. Our gross margin in the second quarter, reflected on Slide 5, was 8.1%, which was down from 8.9% in the same quarter last year. However, our gross margin did improve sequentially from 7.7% posted in the first quarter of this fiscal year. Our decline in gross margin in the current year quarter compared to a year ago was due in part to the impact on yields and higher cost associated with the support of new product introductions as well as higher domestic healthcare cost during the current quarter. Selling and administrative expenses, Slide 6 in the deck, were $10.8 million in the second quarter, which were up $2.5 million in absolute dollars, and up 60 basis points compared to the prior year second quarter. The increase in selling and administrative absolute dollars compared to prior year was in part due to higher stock compensation which accounted for a 20 basis point increase. Also contributing to the S&A increase are increases in employee salaries and related benefit cost, mostly associated with higher employee count, and expense related to the normal revaluation of the supplemental employee retirement plan or SERP liability. As a reminder, the expense related to the revaluation of the SERP liability recorded in selling and administrative expenses is exactly offset by a gain in the investment in the SERP that is recognized in other income/expense, net. Therefore, the impact from the revaluation of the SERP is neutral to net income. Our operating income on Slide 7 in the deck came in at $10.2 million, or 3.9% of net sales, which compares to operating income of $12.2 million or 5.3% of net sales a year ago. Other income/expense, net was an income of $400,000 in the fiscal year 2018 second quarter, compared to an expense of $1 million in the second quarter of fiscal year 2017. During the current year second quarter, other income/expense, net includes a $300,000 gain on the fair value of investments in the SERP. The prior year second quarter other income/expense, net was primarily the result of net foreign currency exchange losses driven by the strengthening of the U.S. dollar a year ago. Our effective tax rate for the current year second quarter was significantly impacted by enactment during the quarter of the U.S. Tax Cuts and Jobs Act, the tax reform. The tax reform lowered the U.S. corporate federal tax rate from 35% to ultimately 21%. However, as we are a June 30 fiscal year end, our current fiscal year blended federal statutory rate will be 28.1%, with the new 21% rate kicking in for our fiscal year 2019. While we applaud this move of lowering the corporate federal tax rate and believe this is positive for U.S. businesses and expect in the long run it will improve the competitiveness of U.S. businesses in the global market, it did have a significant unfavorable impact for us during the current quarter. The tax reform imposed a one-time deemed repatriation tax on accumulated unremitted foreign earnings of 15.5% for the accumulated unremitted foreign earnings held in cash and other liquid assets, and 8% of the residual accumulated unremitted foreign earnings. We estimated and recorded in the current quarter approximately $12.8 million of tax expense for the deemed repatriation tax, which is payable over an eight-year period. In addition, as a result of the change in the U.S. statutory rates, we were required to revalue our deferred tax assets as of December 31, 2017 using the new rates, which resulted in the recording of additional tax expense in the current quarter of approximately $3.8 million. These discrete tax items had a $0.62 unfavorable impact to diluted earnings per share for the quarter. Slide 8 reflects our net income trend. In the second quarter of fiscal year 2018, we recognized an $8.3 million net loss as a result of the tax reform. However, our non-GAAP adjusted net income for the current quarter, excluding the discrete tax items related to tax reform, was $8.2 million, which compares to net income of $7.8 million recorded in the prior year second quarter. We recognized a dilutive loss per share of $0.31 in the current year second quarter, while our non-GAAP adjusted diluted EPS was income of $0.31, which excludes the $0.62 impact from the discrete tax reform items. Diluted EPS in the prior year second quarter was $0.28. Cash and cash equivalents at December 31, 2017 were $35.6 million. Operating cash flow trends are shown on Slide 11. Our cash flow from operations during the current year second quarter was a strong $11.6 million, as our net loss adjusted for depreciation, income tax charges related to tax reform, and an increase in accounts payable more than offset usage of cash related to an increase in inventory. Our cash flow from operating activities in the prior year second quarter was $12.1 million. Our cash conversion days increased one day for the three months ended December 31, 2017 when compared to the same period in the prior year, as our PDSOH, our Production Days Sales on Hand, which is our inventory metric, increased by six days to support increased volumes and new introductions and implementation of new inventory management program for one of our largest medical customers, which more than offset an increase in our accounts payable days compared to the prior year quarter and a reduction in our days sales outstanding receivables metric. Slide 12 reflects our capital and depreciation trend. Capital investments in the second quarter totaled $8.7 million, largely related to our investment in new manufacturing equipment to support increased manufacturing capacity, and new product awards. As Don mentioned, we repurchased $3 million of our common stock during the quarter. Borrowings on our credit facilities at December 31, 2017 were $11 million, which was up $1 million from June 30 of 2017. Our short-term liquidity available, represented as cash and cash equivalents plus the unused amount of our credit facilities, totaled $96 million at December 31, 2017. I would like to conclude by saying, our balance sheet is very strong and we are well positioned to support our continued growth. With that, I would like to open up today's call to questions from our analysts. Michelle, do we have any analysts with questions in the queue?